Bristol Myers Squibb announces phase III CheckMate -816 trial of nivolumab met its primary endpoint in patients with resectable non-small cell lung cancer

Study in 358 patients randomised to 360mg nivolumab plus histology-based platinum doublet chemotherapy every 3 weeks for up to 3 doses, or chemotherapy alone, met its primary endpoint of pathologic complete response.

Source:

Biospace Inc.